|
|
Volumn 98, Issue 5, 2015, Pages 469-471
|
|
Current thinking on the mechanistic basis of Alzheimer's and implications for drug development
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADUCANUMAB;
ALPHA SECRETASE;
AMYLOID BETA PROTEIN;
AMYLOID BETA PROTEIN ANTIBODY;
AMYLOID BETA PROTEIN[1-42];
AMYLOID PRECURSOR PROTEIN;
ANTIBODY;
APOLIPOPROTEIN E;
BAPINEUZUMAB;
BETA SECRETASE INHIBITOR;
CHOLINESTERASE INHIBITOR;
CRENEZUMAB;
GAMMA SECRETASE;
GAMMA SECRETASE INHIBITOR;
GANTENERUMAB;
GLUTAMATE RECEPTOR ANTAGONIST;
N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;
PLACEBO;
SEMAGACESTAT;
SOLANEZUMAB;
TAU PROTEIN;
TAU PROTEIN ANTIBODY;
TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2;
UNCLASSIFIED DRUG;
MAPT PROTEIN, HUMAN;
ACTIVE IMMUNIZATION;
ALZHEIMER DISEASE;
AMYLOID PLAQUE;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TARGETING;
DRUG TOLERABILITY;
GENE MUTATION;
GENETIC RISK;
GENOME-WIDE ASSOCIATION STUDY;
HUMAN;
IMMUNOTHERAPY;
INNATE IMMUNITY;
NERVOUS SYSTEM INFLAMMATION;
NEUROFIBRILLARY TANGLE;
NONHUMAN;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROTEIN AGGREGATION;
PROTEIN CONFORMATION;
PROTEIN PHOSPHORYLATION;
REVIEW;
ANTAGONISTS AND INHIBITORS;
BRAIN;
DRUG DEVELOPMENT;
DRUG EFFECTS;
METABOLISM;
PATHOLOGY;
PROCEDURES;
THINKING;
ALZHEIMER DISEASE;
AMYLOID BETA-PEPTIDES;
BRAIN;
DRUG DISCOVERY;
HUMANS;
IMMUNOTHERAPY;
TAU PROTEINS;
THINKING;
|
|
EID: 84951816455
PISSN: 00099236
EISSN: 15326535
Source Type: Journal
DOI: 10.1002/cpt.200 Document Type: Review |
|
Times cited : (50)
|
|
References (5)
|
